India · Delayed Price · Currency is INR Bal Pharma Statistics
Total Valuation
Bal Pharma has a market cap or net worth of INR 1.71 billion. The enterprise value is 3.21 billion.
| Market Cap | 1.71B |
| Enterprise Value | 3.21B |
Important Dates
The next confirmed earnings date is Saturday, November 14, 2026.
| Earnings Date | Nov 14, 2026 |
| Ex-Dividend Date | Sep 17, 2026 |
Share Statistics
Bal Pharma has 15.92 million shares outstanding. The number of shares has increased by 2.39% in one year.
| Current Share Class | 15.92M |
| Shares Outstanding | 15.92M |
| Shares Change (YoY) | +2.39% |
| Shares Change (QoQ) | -0.48% |
| Owned by Insiders (%) | 52.16% |
| Owned by Institutions (%) | n/a |
| Float | 5.46M |
Valuation Ratios
The trailing PE ratio is 23.87.
| PE Ratio | 23.87 |
| Forward PE | n/a |
| PS Ratio | 0.51 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | 13.93 |
| P/OCF Ratio | 5.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.22, with an EV/FCF ratio of 26.17.
| EV / Earnings | 44.59 |
| EV / Sales | 0.96 |
| EV / EBITDA | 9.22 |
| EV / EBIT | 14.31 |
| EV / FCF | 26.17 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 1.94 |
| Debt / EBITDA | 4.58 |
| Debt / FCF | 12.99 |
| Interest Coverage | 1.30 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 9.51% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 7.59% |
| Revenue Per Employee | 3.56M |
| Profits Per Employee | 76,747 |
| Employee Count | 939 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.86M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.17% in the last 52 weeks. The beta is 0.45, so Bal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +20.17% |
| 50-Day Moving Average | 87.81 |
| 200-Day Moving Average | 78.81 |
| Relative Strength Index (RSI) | 70.62 |
| Average Volume (20 Days) | 8,713 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bal Pharma had revenue of INR 3.34 billion and earned 72.07 million in profits. Earnings per share was 4.50.
| Revenue | 3.34B |
| Gross Profit | 1.59B |
| Operating Income | 224.50M |
| Pretax Income | 68.63M |
| Net Income | 72.07M |
| EBITDA | 348.60M |
| EBIT | 224.50M |
| Earnings Per Share (EPS) | 4.50 |
Balance Sheet
The company has 92.92 million in cash and 1.60 billion in debt, with a net cash position of -1.50 billion or -94.36 per share.
| Cash & Cash Equivalents | 92.92M |
| Total Debt | 1.60B |
| Net Cash | -1.50B |
| Net Cash Per Share | -94.36 |
| Equity (Book Value) | 822.52M |
| Book Value Per Share | 51.71 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 308.35 million and capital expenditures -185.55 million, giving a free cash flow of 122.81 million.
| Operating Cash Flow | 308.35M |
| Capital Expenditures | -185.55M |
| Depreciation & Amortization | 124.10M |
| Net Borrowing | 91.36M |
| Free Cash Flow | 122.81M |
| FCF Per Share | 7.71 |
Margins
Gross margin is 47.50%, with operating and profit margins of 6.71% and 2.16%.
| Gross Margin | 47.50% |
| Operating Margin | 6.71% |
| Pretax Margin | 2.05% |
| Profit Margin | 2.16% |
| EBITDA Margin | 10.42% |
| EBIT Margin | 6.71% |
| FCF Margin | 3.94% |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.36%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.36% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.39% |
| Shareholder Yield | -1.03% |
| Earnings Yield | 4.21% |
| FCF Yield | 7.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |